SEARCH:   Advanced

Blood, 1 June 2004, Vol. 103, No. 11, pp. 4251-4258. Prepublished online as a Blood First Edition Paper on February 19, 2004; DOI 10.1182/blood-2003-07-2365. This Article Full Text (PDF) All Versions of this Article: 2003-07-2365v1 103/11/4251    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Rimsza, L. M Articles by Grogan, T. M Search for Related Content PubMed PubMed Citation Articles by Rimsza, L. M Articles by Grogan, T. M Social Bookmarking                   What's this? Submitted July 22, 2003 Accepted December 29, 2003 Loss of MHC Class II Gene and Protein Expression in Diffuse Large B Cell Lymphoma is Related to Decreased Tumor Immunosurveillance and Poor Patient Survival Irrespective of other Prognostic Factors: A Follow-up Study from the Leukemia and Lymphoma Molecular Profiling Project Lisa M Rimsza*, Robin A Roberts, Thomas P Miller, Joseph M Unger, Michael LeBlanc, Rita M Braziel, Dennis D Weisenburger, Wing C Chan, Timothy C Greiner, H K Muller-Hermelink, Elaine S Jaffe, Randy D Gascoyne, Elias Campo, Deborah A Fuchs, Catherine M Spier, Richard I Fisher, Jan Delabie, Andreas Rosenwald, Louis M Staudt, and Thomas M Grogan Pathology, University of Arizona, Tucson, AZ, USA Arizona Cancer Center, Tucson, AZ, USA Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA Pathology, Oregon Health Sciences Center, Portland, OR, USA Pathology and Microbiology, University of Nebraska, Omaha, NE, USA Pathology, University of Wuerzburg, Wuerzburg, Germany Metabolism Branch, National Cancer Institute, Bethesda, MD, USA British Columbia Cancer Agency, Vancouver, BC, Canada Hospital Clinic Provincial, University of Barcelona, Barcelona, Spain James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA Norwegian Radium Hospital, Oslo, Norway * Corresponding author; email: rimsza{at}ahsc.arizona.edu. The Leukemia and Lymphoma Molecular Profiling Project recently published results from DNA microarray analyses of 240 diffuse large B cell lymphomas (DLBCL). Four gene expression signatures were identified as correlated with patient outcome including the major histocompatibility complex (MHC) Class II genes (e.g. HLA-DRA) which correlated with better survival. We further analyzed the effects of HLA-DRA on survival and correlated gene expression with protein status and tumor infiltrating lymphocytes. Five-year overall survival was 24% in the lowest 10%, 37% in the 10%-25%, 50% in the 25-50%, and 55% for patients in the highest 50% of HLA-DRA expression. Further analysis demonstrated the hazard ratio of death was a non-linear function of HLA-DRA expression. Adjustment for the International Prognostic Index did not alter the impact of HLA-DRA on survival. Other MHC Class II genes were found to predict survival similarly. Microarray HLA-DRA expression correlated with the presence or absence of HLA-DR protein in 20/22 cases assessed. Fewer tumor infiltrating CD8+ T cells were detected in MHC Class II (-) cases compared to (+) cases (2.9 vs. 10.9%, p=0.001), supporting the hypothesis that loss of tumor immunosurveillance has a devastating effect on patient outcome in DLBCL. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. M. Donson, D. K. Birks, V. N. Barton, Q. Wei, B. K. Kleinschmidt-DeMasters, M. H. Handler, A. E. Waziri, M. Wang, and N. K. Foreman Immune Gene and Cell Enrichment Is Associated with a Good Prognosis in Ependymoma J. Immunol., December 1, 2009; 183(11): 7428 - 7440. [Abstract] [Full Text] [PDF] H.-W. Bernd, M. Ziepert, C. Thorns, W. Klapper, H.-H. Wacker, M. Hummel, H. Stein, M.-L. Hansmann, G. Ott, A. Rosenwald, et al. Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials Haematologica, November 1, 2009; 94(11): 1569 - 1580. [Abstract] [Full Text] [PDF] G. Lenz, G. Wright, S.S. Dave, W. Xiao, J. Powell, H. Zhao, W. Xu, B. Tan, N. Goldschmidt, J. Iqbal, et al. Stromal Gene Signatures in Large-B-Cell Lymphomas N. Engl. J. Med., November 27, 2008; 359(22): 2313 - 2323. [Abstract] [Full Text] [PDF] A. De Lerma Barbaro, A. De Ambrosis, B. Banelli, G. L. Pira, O. Aresu, M. Romani, S. Ferrini, and R. S. Accolla Methylation of CIITA promoter IV causes loss of HLA-II inducibility by IFN-{gamma} in promyelocytic cells Int. Immunol., November 1, 2008; 20(11): 1457 - 1466. [Abstract] [Full Text] [PDF] L. M. Rimsza, M. L. LeBlanc, J. M. Unger, T. P. Miller, T. M. Grogan, D. O. Persky, R. R. Martel, C. M. Sabalos, B. Seligmann, R. M. Braziel, et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP Blood, October 15, 2008; 112(8): 3425 - 3433. [Abstract] [Full Text] [PDF] K.-C. Chang and D. Jones Reply to the Letter to the Editor from Oudejans et al Clin. Cancer Res., April 15, 2008; 14(8): 2515 - 2515. [Full Text] [PDF] K.-C. Chang, G.-C. Huang, D. Jones, and Y.-H. Lin Distribution Patterns of Dendritic Cells and T Cells in Diffuse Large B-Cell Lymphomas Correlate with Prognoses Clin. Cancer Res., November 15, 2007; 13(22): 6666 - 6672. [Abstract] [Full Text] [PDF] A. Diepstra, G. W. van Imhoff, H. E. Karim-Kos, A. van den Berg, G. J. te Meerman, M. Niens, I. M. Nolte, E. Bastiaannet, M. Schaapveld, E. Vellenga, et al. HLA Class II Expression by Hodgkin Reed-Sternberg Cells Is an Independent Prognostic Factor in Classical Hodgkin's Lymphoma J. Clin. Oncol., July 20, 2007; 25(21): 3101 - 3108. [Abstract] [Full Text] [PDF] A Plonquet, C Haioun, J-P Jais, A-L Debard, G Salles, M-C Bene, P Feugier, C Rabian, O Casasnovas, M Labalette, et al. Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2 3 diffuse large B-cell lymphoma Ann. Onc., July 1, 2007; 18(7): 1209 - 1215. [Abstract] [Full Text] [PDF] H Veelken, S Vik Dannheim, J Schulte Moenting, U. Martens, J Finke, and A Schmitt-Graeff Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy Ann. Onc., May 1, 2007; 18(5): 931 - 939. [Abstract] [Full Text] [PDF] Z.-Z. Yang, A. J. Novak, S. C. Ziesmer, T. E. Witzig, and S. M. Ansell Attenuation of CD8+ T-Cell Function by CD4+CD25+ Regulatory T Cells in B-Cell Non-Hodgkin's Lymphoma. Cancer Res., October 15, 2006; 66(20): 10145 - 10152. [Abstract] [Full Text] [PDF] R. Chakraverty, H.-S. Eom, J. Sachs, J. Buchli, P. Cotter, R. Hsu, G. Zhao, and M. Sykes Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions Blood, September 15, 2006; 108(6): 2106 - 2113. [Abstract] [Full Text] [PDF] R. A. Roberts, G. Wright, A. R. Rosenwald, M. A. Jaramillo, T. M. Grogan, T. P. Miller, Y. Frutiger, W. C. Chan, R. D. Gascoyne, G. Ott, et al. Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival Blood, July 1, 2006; 108(1): 311 - 318. [Abstract] [Full Text] [PDF] A. Anichini, R. Mortarini, D. Nonaka, A. Molla, C. Vegetti, E. Montaldi, X. Wang, and S. Ferrone Association of Antigen-Processing Machinery and HLA Antigen Phenotype of Melanoma Cells with Survival in American Joint Committee on Cancer Stage III and IV Melanoma Patients. Cancer Res., June 15, 2006; 66(12): 6405 - 6411. [Abstract] [Full Text] [PDF] M. Booman, J. Douwes, A. M. Glas, S. A. Riemersma, E. S. Jordanova, K. Kok, A. Rosenwald, D. de Jong, E. Schuuring, and P. M. Kluin Mechanisms and Effects of Loss of Human Leukocyte Antigen Class II Expression in Immune-Privileged Site-Associated B-Cell Lymphoma. Clin. Cancer Res., May 1, 2006; 12(9): 2698 - 2705. [Abstract] [Full Text] [PDF] I. S. Lossos and D. Morgensztern Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma J. Clin. Oncol., February 20, 2006; 24(6): 995 - 1007. [Abstract] [Full Text] [PDF] M. Gialitakis, A. Kretsovali, C. Spilianakis, L. Kravariti, J. Mages, R. Hoffmann, A. K. Hatzopoulos, and J. Papamatheakis Coordinated changes of histone modifications and HDAC mobilization regulate the induction of MHC class II genes by Trichostatin A Nucleic Acids Res., February 1, 2006; 34(3): 765 - 772. [Abstract] [Full Text] [PDF] L. M. Rimsza, R. A. Roberts, E. Campo, T. M. Grogan, S. Bea, I. Salaverria, A. Zettl, A. Rosenwald, G. Ott, H. K. Muller-Hermelink, et al. Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions Blood, February 1, 2006; 107(3): 1101 - 1107. [Abstract] [Full Text] [PDF] S. Abouzahr, G. Bismuth, C. Gaudin, O. Caroll, P. Van Endert, A. Jalil, J. Dausset, I. Vergnon, C. Richon, A. Kauffmann, et al. Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure PNAS, January 31, 2006; 103(5): 1428 - 1433. [Abstract] [Full Text] [PDF] M. E. Tome, D. B. F. Johnson, L. M. Rimsza, R. A. Roberts, T. M. Grogan, T. P. Miller, L. W. Oberley, and M. M. Briehl A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis Blood, November 15, 2005; 106(10): 3594 - 3601. [Abstract] [Full Text] [PDF] S. Bea, A. Zettl, G. Wright, I. Salaverria, P. Jehn, V. Moreno, C. Burek, G. Ott, X. Puig, L. Yang, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction Blood, November 1, 2005; 106(9): 3183 - 3190. [Abstract] [Full Text] [PDF] I. S. Lossos Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma J. Clin. Oncol., September 10, 2005; 23(26): 6351 - 6357. [Abstract] [Full Text] [PDF] T. Tsuji, M. Yasukawa, J. Matsuzaki, T. Ohkuri, K. Chamoto, D. Wakita, T. Azuma, H. Niiya, H. Miyoshi, K. Kuzushima, et al. Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes Blood, July 15, 2005; 106(2): 470 - 476. [Abstract] [Full Text] [PDF] J. W. Sweetenham Diffuse Large B-Cell Lymphoma: Risk Stratification and Management of Relapsed Disease Hematology, January 1, 2005; 2005(1): 252 - 259. [Abstract] [Full Text] [PDF] A. C. Borczuk, L. Shah, G. D. N. Pearson, K. L. Walter, L. Wang, J. H. M. Austin, R. A. Friedman, and C. A. Powell Molecular Signatures in Biopsy Specimens of Lung Cancer Am. J. Respir. Crit. Care Med., July 15, 2004; 170(2): 167 - 174. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020